key: cord-0849741-83v259fp authors: Nouri‐Vaskeh, Masoud; Kalami, Niusha; Zand, Ramin; Soroureddin, Zahra; Varshochi, Mojtaba; Ansarin, Khalil; Rezaee, Haleh; Taghizadieh, Ali; Sadeghi, Armin; Ahangari Maleki, Masoud; Esmailnajad, Azam; Saleh, Parviz; Haghdoost, Mehdi; Maleki, Mehdi; Sharifi, Akbar title: Comparison of losartan and amlodipine effects on the outcomes of patient with COVID‐19 and primary hypertension: A randomised clinical trial date: 2021-03-13 journal: Int J Clin Pract DOI: 10.1111/ijcp.14124 sha: 8063fece84e8ea88b8abc37dad6d538ab186c953 doc_id: 849741 cord_uid: 83v259fp BACKGROUND: Controversy exists regarding the drug selection in hypertension (HTN) management in patients with COVID‐19. This study aimed to compare the effects of losartan and amlodipine in patients with primary HTN and COVID‐19. METHODS: In this randomised clinical trial, hospitalised patients with COVID‐19 and primary HTN were enrolled in the study. One arm received losartan, 25 mg, twice a day and the other arm received amlodipine, 5 mg per day for 2 weeks. The main outcomes were compare 30‐day mortality rate and length of hospital stay. RESULTS: The mean age of patients treated with losartan (N = 41) and amlodipine (N = 39) was 67.3 ± 14.8 and 60.1 ± 17.3 years, respectively (P value = .068). The length of hospital stay in losartan and amlodipine groups was 4.57 ± 2.59 and 7.30 ± 8.70 days, respectively (P value = .085). Also, the length of ICU admission in losartan and amlodipine group was 7.13 ± 5.99 and 7.15 ± 9.95 days, respectively (P value = .994). The 30‐day mortality was two and five patients in losartan and amlodipine groups, respectively (P value = .241). CONCLUSIONS: There was no priority in losartan or amlodipine administration in COVID‐19 patients with primary HTN in decreasing mortality rate, hospital and ICU length stay. Further studies need to clarify the first‐line anti‐HTN medications in COVID‐19. The current study was a prospective randomised clinical trial in order to compare the effects of losartan and amlodipine in primary HTN management of patients with COVID-19. The study was approved by the Medical Ethical Committee of Tabriz University of Medical Sciences and was registered at Iranian Registry for Clinical Trials (IRCT ID: IRCT20180802040678N4) on 1 April 2020. Informed consent was obtained from patients before enrolment. Patients with COVID-19 and primary HTN were recruited to the study in Imam Reza Hospital of Tabriz University of Medical Sciences in Tabriz, Iran, from 2 April 2020 to 30 June 2020. Inclusion criteria were the following: age 18 years and older, patients with primary HTN with systolic blood pressure (SBP) level of 130-140 mmHg and diastolic blood pressure (DBP) of 85-90 mmHg who were managed by non-pharmacological strategies or were newly diagnosed. Exclusion criteria were pregnant and lactating patients, severe hepatic and renal failure, bilateral renal artery stenosis and patients with the history of uncontrolled HTN, and also patients showing losartan side effects such as cough exacerbation, increased potassium levels in blood and baseline, new anaemia, shock or reduction of blood pressure 90/60 mmHg or less, all had been excluded. The patients were randomised (randomly assigned 1:1) according to inclusion and exclusion criteria and via block randomisation in both groups. Randomisation was done by a computer-generated What's new • There was no priority in losartan or amlodipine administration in COVID-19 patients with primary HTN in decreasing mortality rate. • There was no priority in losartan or amlodipine administration in COVID-19 patients with primary HTN in decreasing hospital length stay. • There was no priority in losartan or amlodipine administration in COVID-19 patients with primary HTN in decreasing ICU length stay. random number for the assignment of participants to the losartan or amlodipine arm. A researcher who was not involved in our survey conducted the allocation in order to maintain blinding. Till the achievement and assessment of all data, submitted cases who received drug administration and analysing the results remained blind via randomised and allocated processes. Besides standard treatment, supportive and symptomatic therapy in both groups, in losartan group patients was received 25 mg losartan (Actoverco, Karaj, Iran) tablets twice per day (before breakfast and after dinner) and in amlodipine group patients was received amlodipine besilate 5 mg (Actoverco, Karaj, Iran) per day at least for 14 days. In intubated patients, the drugs were continued using nasogastric tube. The study design is shown in Figure 1 . In the primary examination by a pulmonologist, demographic data including age and sex, and also medical history or co-morbidities were extracted. Furthermore, clinical characteristics were also obtained. In all cases, chest computed tomography (CT) scan was done, and before commencing the interview, all laboratory information were collected. In this study, the primary outcomes were comparison of 30-days mortality and length of hospital stay between groups. The secondary outcomes were disease severity assessment, needs to intubation, laboratory and clinical parameters change. Disease severity was assessed by sequential organ failure assessment F I G U R E 1 Study flow diagram (SOFA) respiratory score. The SOFA assessment is used to assess of critical patients to determine the extent of organ function or rate of failure. Total score is calculated by a SOFA calculator. Total scores range are from 0 to 24, with higher scores indicating greater chance of mortality. 21 The normal distribution of variables was evaluated using the Kolmogorov-Smirnov test. Qualitative and normally distributed quantitative variables were displayed as numbers (percentages) and mean ± standard deviation, respectively. Paired t test was utilised to compare the differences between variables before and after the drug consumption. Chi-squared or independent sample t-test was also used for differences between groups. P value < .05 was considered statistically significant. Data were analysed using SPSS, 24.0 (SPSS Inc, Chicago, IL). Of the patients in the losartan group, 39 (95.1%) were survived and 2 (4.9%) were died. In addition, eight patients (19.5%) were intubated in this group. In the amlodipine group, 34 patients (87.18%) were discharged and 5 patients (12.82%) were died. Also, nine patients (23.08%) were intubated in this group. Morewise, the mean duration of hospitalisation in losartan group was 4.57 ± 2.59 while the mean duration of hospitalisation in amlodipine group was 7.30 ± 8.70 days, that shows more days hospitalisation in controls (P value = .085). Also the length of ICU admission in losartan group was 7.13 ± 5.99 days, while it was 7.15 ± 9.95 days in the amlodipine group that shows more length of ICU admission in amlodipine group (P value > .05). Comparison of outcomes is shown in Table 2 . Characteristics of patients before and after intervention in both groups including cell blood counts, electrolyte profiles, liver and kidney function tests, inflammatory parameters and blood gas analysis are shown in Table 3 . In the losartan group, the mean admission-and discharge-time SOFA score were 3.08 ± 1.35 and 2.42 ± 1.17, respectively (P value = .002). In the amlodipine group, the mean admission-and discharge-time SOFA score was 3.74 ± 2.21 and 4.26 ± 3.71, respectively (P value = .326). The comparison of these groups highlighted no significant difference in disease severity between groups at discharge time (P value = .084). We did not found adverse effects or symptoms with the losartan and amlodipine groups that were related to these medications administration. Clinical characteristics of coronavirus disease 2019 in China Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Fecal transmission in COVID-19: a potential shedding route Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis Clinical characteristics of fatal cases of COVID-19 in Tabriz, Iran: an analysis of 111 patients Is hypertension a real risk factor for poor prognosis in the COVID-19 pandemic? Angiotensin 1-7: a novel strategy in COVID-19 treatment Blood pressure and the new ACC/AHA hypertension guidelines US hypertension management guidelines: a review of the recent past and recommendations for the future Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence? A potential protective role of losartan against coronavirus-induced lung damage Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension Angiotensin-converting enzyme 2 protects from severe acute lung failure Losartan, an antagonist of AT1 receptor for angiotensin II, attenuates lipopolysaccharide-induced acute lung injury in rat Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin II-induced inflammation Regulation of T-cell function by endogenously produced angiotensin II COVID-19) The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/ failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine Effects of angiotensin receptor blockers (ARBs) on in-hospital outcomes of patients with hypertension and confirmed or clinically suspected COVID-19 The coronavirus is most deadly if you are older and male -new data reveal the risks Impact of angiotensinconverting enzyme inhibitors and statins on viral pneumonia Renin-angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on the risk of pneumonia and severe exacerbations in patients with COPD Dyspneic and non-dyspneic (silent) hypoxemia in COVID-19: Possible neurological mechanism Increased expression of angiotensin converting enzyme 2 in conjunction with reduction of neointima by angiotensin II type 1 receptor blockade Angiotensin-converting enzyme 2: the first decade Hypertension: renin-angiotensin-aldosterone system alterations Effect of a strategy of comprehensive vasodilation vs usual care on mortality and heart failure rehospitalization among patients with acute heart failure: the GALACTIC randomized clinical trial Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetes Losartan inhibits conventional dendritic cell maturation and Th1 and Th17 polarization responses: Νovel mechanisms of preventive effects on lipopolysaccharide-induced acute lung injury Nifedipine and amlodipine are associated with improved mortality and decreased risk for intubation and mechanical ventilation in elderly patients hospitalized for COVID-19 Also, all of the patients were Iranian; therefore, the findings might not be generalised in different ethnicity. Possible confounding factors not otherwise accounted for this study was another limitation. In conclusion, there was no priority in losartan or amlodipine ad- The authors declare that there is no conflict of interest. The data that support the findings of this study are available from the corresponding author, AS, upon reasonable request. https://orcid.org/0000-0001-8808-2028